While immunotherapies have revolutionized the treatment of cancer, the large majority of patients with solid tumours still do not respond to them. Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonize solid tumours and remodel their local microenvironment. By removing barriers to immune infiltration in a safe and localized way, Neobe's recombinant live biotherapeutics can potentially double the number of cancer patients that respond to existing immunotherapeutic strategies.
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.Contact Marco